SCHEMBL264857

SCHEMBL264857

CC(=O)Nc1cn(C2CCCC2)c2cc(NC3CCCCC3)c(F)cc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 1/20 0.52
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 4/20 0.42
FOXO1 Q12778 1/20 0.39
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
TOP2A P11388 2/20 0.37
TOP2B Q02880 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
GSK3B P49841 1/20 0.36
CREBBP Q92793 2/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263654 0.87 MEN1 (0.59) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL262122 0.86 MEN1 (0.49) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL263820 0.84 GAA (0.48) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL27763899 0.84 MEN1 (0.48) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL261920 0.84 MEN1 (0.48) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL262114 0.84 MEN1 (0.53) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL262257 0.83 KDM4E (0.58) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL265594 0.83 MEN1 (0.51) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL27743195 0.83 MEN1 (0.52) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL262995 0.83 MEN1 (0.59) MEN1KMT2AGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 MEN1 3327/4885KMT2A 2966/4885GAA 4203/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 MEN1 2994/4885KMT2A 2967/4885GAA 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.